Alembic Pharmaceuticals (APLLTD) Stock Overview
An integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
APLLTD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Alembic Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹943.95 |
| 52 Week High | ₹1,303.90 |
| 52 Week Low | ₹725.20 |
| Beta | 0.47 |
| 1 Month Change | -1.57% |
| 3 Month Change | -3.82% |
| 1 Year Change | -11.52% |
| 3 Year Change | 48.27% |
| 5 Year Change | 2.30% |
| Change since IPO | 1,876.86% |
Recent News & Updates
Analysts Are Updating Their Alembic Pharmaceuticals Limited (NSE:APLLTD) Estimates After Its First-Quarter Results
Aug 08
Alembic Pharmaceuticals Limited's (NSE:APLLTD) P/E Still Appears To Be Reasonable
Jul 11Recent updates
Analysts Are Updating Their Alembic Pharmaceuticals Limited (NSE:APLLTD) Estimates After Its First-Quarter Results
Aug 08Alembic Pharmaceuticals Limited's (NSE:APLLTD) P/E Still Appears To Be Reasonable
Jul 11Here's What Analysts Are Forecasting For Alembic Pharmaceuticals Limited (NSE:APLLTD) After Its Annual Results
May 11What Alembic Pharmaceuticals Limited's (NSE:APLLTD) 25% Share Price Gain Is Not Telling You
Mar 31
Future US Launches And GLP-1 Investments Will Strengthen Market Position
Aggressive U.S. product launch strategy and peptide investments to counter price erosion and drive future high-margin revenue growth.Alembic Pharmaceuticals Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next
Feb 06Why We're Not Concerned About Alembic Pharmaceuticals Limited's (NSE:APLLTD) Share Price
Jan 11Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts
Nov 10Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price
Sep 25Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?
Sep 03Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 13Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher
Jul 20Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?
May 11Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 08Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%
Jan 21Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Apr 13Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jan 04Shareholder Returns
| APLLTD | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.8% | -2.6% | -1.4% |
| 1Y | -11.5% | -6.3% | -7.6% |
Return vs Industry: APLLTD underperformed the Indian Pharmaceuticals industry which returned -6.3% over the past year.
Return vs Market: APLLTD underperformed the Indian Market which returned -7.6% over the past year.
Price Volatility
| APLLTD volatility | |
|---|---|
| APLLTD Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 7.9% |
| 10% least volatile stocks in IN Market | 3.3% |
Stable Share Price: APLLTD has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: APLLTD's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1907 | 16,571 | Chirayu Amin | alembicpharmaceuticals.com |
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products.
Alembic Pharmaceuticals Limited Fundamentals Summary
| APLLTD fundamental statistics | |
|---|---|
| Market cap | ₹185.55b |
| Earnings (TTM) | ₹6.03b |
| Revenue (TTM) | ₹68.21b |
Is APLLTD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APLLTD income statement (TTM) | |
|---|---|
| Revenue | ₹68.21b |
| Cost of Revenue | ₹18.94b |
| Gross Profit | ₹49.27b |
| Other Expenses | ₹43.24b |
| Earnings | ₹6.03b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 30.68 |
| Gross Margin | 72.23% |
| Net Profit Margin | 8.84% |
| Debt/Equity Ratio | 24.2% |
How did APLLTD perform over the long term?
See historical performance and comparisonDividends
Does APLLTD pay a reliable dividends?
See APLLTD dividend history and benchmarks| Alembic Pharmaceuticals dividend dates | |
|---|---|
| Ex Dividend Date | Jul 29 2025 |
| Dividend Pay Date | Sep 04 2025 |
| Days until Ex dividend | 36 days |
| Days until Dividend pay date | 1 day |
Does APLLTD pay a reliable dividends?
See APLLTD dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/02 22:13 |
| End of Day Share Price | 2025/09/02 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alembic Pharmaceuticals Limited is covered by 24 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sarabjit Nangra | Angel Broking Private Limited |
| null null | Antique Stockbroking Ltd. |
| Harith Ahamed | Avendus Spark |